Moderna May Have Put Its Best Days Behind It

InvestorPlace2022-04-15

In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Michrich
2022-04-16
Michrich
Ok
jilimi
2022-04-15
jilimi
👍
Foxie
2022-04-15
Foxie
Good
Steven Tay
2022-04-15
Steven Tay
Like
ShawnKoh1
2022-04-15
ShawnKoh1
Like
SaveHK
2022-04-15
SaveHK
Thanks for sharing this information 👍

Leave a comment

185

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193361549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-15 17:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193361549","market":"us","top_or_hot":-1,"title":"Moderna May Have Put Its Best Days Behind It","media":"InvestorPlace","content":"<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","article_id":"1193361549","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","pubTimestamp":1650015391,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳可能已经把最好的日子抛在脑后了","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9083954372,"gmtCreate":1650069271555,"gmtModify":1676534639234,"author":{"id":"3582343271957983","authorId":"3582343271957983","name":"Michrich","avatar":"https://static.tigerbbs.com/8b1a28d47569c69731121b5b5a424aaf","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3582343271957983","idStr":"3582343271957983"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9083954372","repostId":1193361549,"repostType":2,"repost":{"id":"1193361549","pubTimestamp":1650015391,"share":"https://ttm.financial/m/news/1193361549?lang=&edition=fundamental","pubTime":"2022-04-15 17:36","market":"us","language":"en","title":"Moderna May Have Put Its Best Days Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","media":"InvestorPlace","summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","content":"<html><head></head><body><p>In the short term, MRNA stock is not likely to provide growth that will excite investors</p><p>In the last 30 days, <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.</p><p>Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.</p><p>That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.</p><p>The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.</p><p>And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&amp;D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.</p><p>In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.</p><p>But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193361549","content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9089730210,"gmtCreate":1650032270791,"gmtModify":1676534632554,"author":{"id":"4089552822641240","authorId":"4089552822641240","name":"jilimi","avatar":"https://static.tigerbbs.com/0e2467f98553dd418c9f7848124557f3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4089552822641240","idStr":"4089552822641240"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089730210","repostId":1193361549,"repostType":4,"repost":{"id":"1193361549","pubTimestamp":1650015391,"share":"https://ttm.financial/m/news/1193361549?lang=&edition=fundamental","pubTime":"2022-04-15 17:36","market":"us","language":"en","title":"Moderna May Have Put Its Best Days Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","media":"InvestorPlace","summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","content":"<html><head></head><body><p>In the short term, MRNA stock is not likely to provide growth that will excite investors</p><p>In the last 30 days, <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.</p><p>Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.</p><p>That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.</p><p>The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.</p><p>And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&amp;D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.</p><p>In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.</p><p>But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193361549","content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9089474017,"gmtCreate":1650029745428,"gmtModify":1676534631898,"author":{"id":"3572988793196593","authorId":"3572988793196593","name":"Foxie","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3572988793196593","idStr":"3572988793196593"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089474017","repostId":1193361549,"repostType":4,"repost":{"id":"1193361549","pubTimestamp":1650015391,"share":"https://ttm.financial/m/news/1193361549?lang=&edition=fundamental","pubTime":"2022-04-15 17:36","market":"us","language":"en","title":"Moderna May Have Put Its Best Days Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","media":"InvestorPlace","summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","content":"<html><head></head><body><p>In the short term, MRNA stock is not likely to provide growth that will excite investors</p><p>In the last 30 days, <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.</p><p>Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.</p><p>That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.</p><p>The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.</p><p>And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&amp;D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.</p><p>In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.</p><p>But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193361549","content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9089461129,"gmtCreate":1650023311179,"gmtModify":1676534630753,"author":{"id":"4099285253763630","authorId":"4099285253763630","name":"Steven Tay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4099285253763630","idStr":"4099285253763630"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089461129","repostId":1193361549,"repostType":4,"repost":{"id":"1193361549","pubTimestamp":1650015391,"share":"https://ttm.financial/m/news/1193361549?lang=&edition=fundamental","pubTime":"2022-04-15 17:36","market":"us","language":"en","title":"Moderna May Have Put Its Best Days Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","media":"InvestorPlace","summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","content":"<html><head></head><body><p>In the short term, MRNA stock is not likely to provide growth that will excite investors</p><p>In the last 30 days, <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.</p><p>Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.</p><p>That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.</p><p>The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.</p><p>And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&amp;D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.</p><p>In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.</p><p>But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193361549","content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9089414758,"gmtCreate":1650020637098,"gmtModify":1676534630361,"author":{"id":"3570598542159923","authorId":"3570598542159923","name":"ShawnKoh1","avatar":"https://static.tigerbbs.com/0045c4894f8a2755b17a9e8518df4d5e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3570598542159923","idStr":"3570598542159923"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089414758","repostId":1193361549,"repostType":4,"repost":{"id":"1193361549","pubTimestamp":1650015391,"share":"https://ttm.financial/m/news/1193361549?lang=&edition=fundamental","pubTime":"2022-04-15 17:36","market":"us","language":"en","title":"Moderna May Have Put Its Best Days Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","media":"InvestorPlace","summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","content":"<html><head></head><body><p>In the short term, MRNA stock is not likely to provide growth that will excite investors</p><p>In the last 30 days, <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.</p><p>Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.</p><p>That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.</p><p>The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.</p><p>And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&amp;D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.</p><p>In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.</p><p>But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193361549","content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9089415506,"gmtCreate":1650020439890,"gmtModify":1676534630313,"author":{"id":"3570678493691973","authorId":"3570678493691973","name":"SaveHK","avatar":"https://static.tigerbbs.com/89b74f5799a23844400ed6de94296d38","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3570678493691973","idStr":"3570678493691973"},"htmlText":"Thanks for sharing this information 👍","listText":"Thanks for sharing this information 👍","text":"Thanks for sharing this information 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9089415506","repostId":1193361549,"repostType":4,"repost":{"id":"1193361549","pubTimestamp":1650015391,"share":"https://ttm.financial/m/news/1193361549?lang=&edition=fundamental","pubTime":"2022-04-15 17:36","market":"us","language":"en","title":"Moderna May Have Put Its Best Days Behind It","url":"https://stock-news.laohu8.com/highlight/detail?id=1193361549","media":"InvestorPlace","summary":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last ","content":"<html><head></head><body><p>In the short term, MRNA stock is not likely to provide growth that will excite investors</p><p>In the last 30 days, <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.</p><p>Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.</p><p>That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.</p><p>The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.</p><p>And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&amp;D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.</p><p>In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.</p><p>But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna May Have Put Its Best Days Behind It</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna May Have Put Its Best Days Behind It\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-15 17:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to...</p>\n\n<a href=\"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://investorplace.com/2022/04/mrna-stock-may-have-put-its-best-days-behind-it/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193361549","content_text":"In the short term, MRNA stock is not likely to provide growth that will excite investorsIn the last 30 days, Moderna stock is up nearly 11%. That’s welcome news to investors who bought shares prior to the selloff that started in September. At that time, MRNA stock was trading above $450 per share. However, for many reasons, Moderna is not likely to move significantly higher anytime soon. For that reason, investors should be careful about investing in the long term.Let’s start with the good news. Moderna is projected to generate $21 billion in revenue from its Covid-19 vaccine. That number could go higher, but let’s just stick with that for now.That’s a 13% increase from its 2021 revenue. Double-digit growth is always appreciated. However, it’s a far cry from the growth experienced between 2020 and 2021. That’s to be expected. Nevertheless, it’s likely Moderna will generate lower earnings, which is almost always a drag on a stock price.The company is a leader in mRNA technology, and it does have a couple of other products that are in late-stage clinical trials. But this time around, the biotech giant won’t have Operation Warp Speed serving as a catalyst to get rapid approval. That means it’s likely to be late 2023 and possibly 2024 before a new product works its way through the process.And Moderna does have a robust pipeline of other drugs and therapeutics in its pipeline. These could bring in billions in revenue, but not for several years. And getting them approved will take time and money. Currently Moderna’s research and development (R&D) expenses total about $2 billion annually, but the cost to earnings remains to be seen.In the meantime, other biotech companies that use mRNA technology are likely to put drug candidates into clinical trials. And that makes sense because, according to Vantage Research, the global revenue for mRNA cancer vaccines and therapeutics is expected to be more than $100 billion by 2028. And if Moderna gets other products approved before its competitors, it may have time to pad its lead.But that’s not a guarantee. For this reason, I see MRNA stock as making some sense as a short-term trade, but I would be hesitant to take a long-term position in the stock.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":185,"commentSize":12,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193361549"}